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ABSTRACT
Introduction: The aim of this study was to find
out the evolving role of professional continuous
glucose monitoring (PCGM) on hemoglobin
A1c (HbA1c) and the frequency of
hypoglycemia.
Methods: This was a 3-month, prospective
study conducted among patients (aged
15–24 years) with type 1 diabetes mellitus who
attended a diabetes clinic [Diabetes Treatment
Center, Prince Sultan Military Medical City
(PSMMC), Riyadh, Saudi Arabia] due to
recurrent unexplained hypoglycemia
unawareness episodes between July 2014 and
December 2014. The respondents were
purposively and conveniently selected and
they were asked to wear the PCGM device
(iPro2; Medtronic MiniMed, Inc., Northridge,
CA, USA) for 5 days. The PCGM results were
collected by the diabetic educator and reviewed
by the treating physician on the same day as
removal of the device. Clinical and
demographic data were also collected.
Results: Overall, 56 patients were included in
the study. The mean (±SD) age of the study
cohort was 18.1 ± 1.82 years and 27 (48.2%)
patients were male. Compared with baseline,
non-significant but positive differences were
observed in HbA1c levels in both male and
female patients and in those who were older
(aged 20–24 years). Similar results were
observed in the frequency of hypoglycemia
and a significant change was observed for
female patients (P\0.05). Compared with
baseline, a significant positive difference was
observed in patients’ overall frequency of
hypoglycemia by the end of the study
(P\0.001).
Conclusions: Professional continuous glucose
monitoring is a valuable tool for detecting
episodes of hypoglycemia and may help to
decrease HbA1c levels and reduce the
frequency of hypoglycemia.
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INTRODUCTION
The latest International Diabetes Federation
statistics suggest that Saudi Arabia has one of
the highest percentages of diabetes sufferers in
the world, which in turn means an increase in
the number of diabetes-related complications
[1, 2]. Studies report that almost 1 in4people over
30 years of age has diabetes and that healthcare
expenses incurred by people with diabetes have
risen more than 500% in the last 18 years [3, 4].
Furthermore,poordiabetes self-caremanagement
and a low adherence to medication are high
among the Saudi population [5].
The current goal in diabetesmanagement is to
lower hemoglobin A1c (HbA1c), to target levels
and to prevent diabetes-related complications
while avoiding hypoglycemia [6]. Patients with
diabetes are asked to reduce their HbA1c levels; as
such, an increased need for more frequent and
comprehensive glucose information with better
hypoglycemia detection has led to the
development of continuous glucose monitoring
(CGM) technology [6].
Today, there are a large number of
technologies available to assist with diabetes
care. To maximize the benefits of this
technology, it is essential that both clinicians
and patients are involved. Recent clinical practice
guidelines by the Endocrine Society suggest that
patients aged 8 years and above who are offered
CGMcan benefit from this new technology [7, 8].
Professional continuous glucose monitoring
(PCGM) technology supports clinicians in
gaining a more complete insight into their
patient’s glycemic profiles, variations in their
lifestyle or dietary intake, and their therapeutic
interventions [9]. Over the past 10 years, PCGM
has also evolved from being a research tool to
being a device that is useful in daily clinical
practice [10]. Designed to improve glucose
control without the addition of medication,
CGM may have the potential to increase the
proportion of patients who are able to maintain
target HbA1c values while simultaneously
limiting the risk of severe hypoglycemia [7, 8,
10–12]. Also, research shows that the use of rapid
and long-acting insulin analogs, improvements
in insulin pumps, and repeated home blood
glucose monitoring have had a positive effect on
the ability of patients with type 1 diabetes
mellitus (T1DM) to achieve target HbA1c levels
[11]. However, rates of severe hypoglycemia
remain too high and the occurrence of such
events is often followed by a decline in glycemic
control due to fears of further hypoglycemic
episodes [11, 13]. This may also be due to
circadian glycemic fluctuations and partially
due to the lack of continuous feedback
information on glucose levels after meals or
during the night, although follow-up studies
report a decreasing incidence [11, 13]. As a
result, this represents the most significant
barrier to achieving HbA1c target levels, in
addition to its deleterious effects on the health
and well-being of affected patients [11, 13].
It has never been easier to discover earlier the
undetected high and low glucose excursions
and to understand their causes. This data is
supportive for making better treatment
decisions to improve patients’ lives. The
iPro2 (Medtronic MiniMed, Inc., Northridge,
CA, USA) PCGM device is quick to implement
and provides reports that physicians can use to
educate patients on the therapy and lifestyle
changes they can make to improve their health
and quality of life. In the present study, the
authors aimed to find out the impact of PCGM
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on patients HbA1c levels and the frequency of
hypoglycemia.
METHODS
Study Design and Setting
This was a 3-month, prospective study
conducted among patients (aged 15–24 years)
with T1DM at the Diabetes Treatment Center,
Prince Sultan Military Medical City (PSMMC),
Riyadh, Saudi Arabia between July 2014 and
December 2014. All patients had a diagnosis of
T1DM according to the practice guidelines of
the American Diabetes Association (ADA) [14].
Patients Selection and Compliance
with Ethics Guidelines
Participants were selected according to their
availability during their visit to the diabetes
clinic. This study was conducted in accordance
with the Helsinki Declaration of 1964, as revised
in 2013, and the protocol of this study was
approved by the research ethics committee of
the PSMMC. All the patients were informed
about the purpose and methods of the research
both verbally and in written form. Written
consent was obtained from patients before the
completion of study measurement. Study
participants were free to withdraw from the
study at any time without giving a reason.
During the baseline visit, socio-demographic,
clinical data and patients treatment types, i.e.,
multiple daily injections (MDI) and insulin
pump (IP) were collected.
Inclusion and Exclusion Criteria
Patients aged 15–24 years who had been
followed up for at least 6 months and who did
not have any other concomitant chronic
disease were included. Exclusion criteria were
adolescents who had a history of
psychopathological and medical instability or
visual, hearing, or cognitive impairment.
Glycosylated Hemoglobin
and Hypoglycemia
The HbA1c test was the most appropriate
measure of glycemic control and diagnostic
test for diabetes. HbA1c\ 7% was considered a
good control value (ADA standards of medical
care in diabetes) [14]. HbA1c levels were
measured at baseline and 3 months. Readings
were collected from the patients’ records which
are analyzed in the central lab at PSMMC
(COBAS INTEGRA 400 plus/800 analyzers).
Reports for PCGM were generated quickly
within 1 day of removal of the device to
identify patterns and to make the correct
therapy adjustments by the same investigator.
Hypoglycemia was defined as any blood
glucose value B70 mg/dL (B3.9 mmol/L). The
frequency of hypoglycemia data was collected
from patients’ PCGM report [15].
iPro2 and Measures
A continuous glucose monitor is a minimally
invasive device that is designed to measure and
record glucose levels continuously and
automatically in patients with diabetes
mellitus [16]. The PCGM equipment is owned
by the healthcare professional and is typically
worn by the patient for 5 days. With PCGM, the
patient remains unaware of blood glucose
monitoring results until they are downloaded
and analyzed by the healthcare professional
with no alarms or inconvenience and requires
minimum patient training when compared
with real-time CGM, and patients do not
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receive glucose alerts and only see the PCGM
data after it has been analyzed by the healthcare
professional.
The iPro2 device was used over a 5-day
period in a blinded fashion exclusively for
CGM in all patients. The iPro2 was placed on
and removed from the patient by a trained
diabetic educator and all patients were advised
to do four finger stick tests per day for
calibration. The information was delivered to
the treating physician within a day of removal
of the device. The patients were educated to do
routine self-monitoring of blood glucose
(SMBG) and to record their dietary intake and
activity during the test period. The test was
ideally done on days that were representative of
‘‘typical’’ days. The results of iPro2 were
discussed with the patients/care givers to make
modifications concerning various factors
influencing the patient’s diabetes control,
adjustments in insulin doses, and therapeutic
treatment recommendations, including
changes in diet, activity, and medication.
Statistical Analysis
Data analysis was performed using Excel 2010
(Microsoft Corporation, Seattle, WA, USA) and
SPSS version 16 (SPSS Inc., Chicago, IL, USA). In
addition to descriptive analysis, t tests were used
to look for differences between the groups and
between baseline to 3 months. A P value of
\0.05 was considered statistically significant.
RESULTS
Overall, 56 patients were enrolled in the study.
The mean (±SD) age of the study cohort was
18.1 ± 1.82 years. Twenty-seven patients were
male (48.2%) and 29 were female (51.8%;
Table 1). More than 75% of the study
population were receiving MDI treatment.
Table 1 shows the impact of PCGM on
HbA1c and frequency of hypoglycemia.
Compared with baseline, non-significant but
positive differences were observed in HbA1c
levels at 3 months in both male and female
patients. Similarly, non-significant but positive
differences were observed in patients aged
15–19 years and patients aged 20–24 years.
Both treatment groups (MDI, IP) showed
positive differences at 3 months compared
with baseline. However, no significant
differences in HbA1c levels were observed
between genders, age groups, and different
treatments groups.
Positive reductions were observed in the
frequency of hypoglycemia at 3 months in
both male and female patients when
compared with baseline. Similar results were
observed in the different age groups and the
different treatment groups. It is important to
note here that, when compared with male
patients, females showed a significant
reduction in the frequency of hypoglycemia
(P\0.05). However, no significant differences
were observed between the different age groups
and the different treatments groups (Table 1).
The impact of PCGM on overall HbA1c level
is illustrated in Fig. 1. Compared with baseline,
an non-significant but positive difference
(0.42%, P = 0.073) was observed in HbA1c
levels at 3 months. Compared to baseline, a
positive significant difference was observed in
the overall frequency of hypoglycemia at
3 months (P\0.001); Fig. 2.
DISCUSSION
People with diabetes face a life-long
optimization problem to continue glycemic
control without increasing their risk of
hypoglycemia [17]. The developing trends in
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technology and therapeutic strategies create a
very exciting time for the management of
diabetes [18]. PCGM, being relatively novel
technology, has been shown to be helpful and
offers the potential to improve care for patients
with T1DM beyond what can be achieved with
SMBG alone [19]. In the present study, the
authors aimed to discover the evolving role of
PCGM on HbA1c levels and the frequency of
hypoglycemia. It was found that, when
compared with baseline, positive (but non-
significant) differences were observed in
HbA1c levels among genders, different age
groups, and different treatment groups. The
overall HbA1c levels also showed positive
decline. In contrast to our findings, in a
Table 1 The impact of professional continuous glucose monitoring on HbA1c levels and the frequency of hypoglycemia
Variables n, % HbA1c level, % Frequency of hypoglycemia, n
Baseline 3 months Baseline 3 months
Gender
Male 27 (48.2%) 8.61 ± 0.49 8.36 ± 0.23 2.56 ± 0.69 2.04 ± 0.19
Female 29 (51.8%) 8.95 ± 0.66 8.47 ± 0.54 2.63 ± 0.5 1.6 ± 0.5*
Age, years
15–19 35 (62.5%) 8.91 ± 0.63 8.51 ± 0.42 2.59 ± 0.56 1.93 ± 0.25
20–24 21 (37.5%) 8.68 ± 0.47 8.31 ± 0.41 2.56 ± 0.72 1.72 ± 0.57
Treatment type
MDI 44 (78.6%) 8.76 ± 0.57 8.57 ± 0.42 2.69 ± 0.57 1.89 ± 0.31
IP 12 (21.4%) 8.85 ± 0.62 8.12 ± 0.43 2.18 ± 0.62 1.73 ± 0.64
Values are presented as mean ± standard deviation. Groups were compared by t test
HbA1c hemoglobin A1c, IP insulin pump, MDI multiple daily injections
* P\0.05, male vs. female
Fig. 1 The impact of professional continuous glucose monitoring on HbA1c levels. Values are presented as
mean ± standard deviation. Baseline vs. 3 months compared by t test. HbA1c hemoglobin A1c
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retrospective study, short-term blinded PCGM
using the device in a private practice setting was
reported to be ineffective for improving HbA1c
levels in adult patients with type 1 and 2
diabetes [12]. Furthermore, the authors
reported that before blinded CGM the average
HbA1c level was 7.7 ± 1.0% and after it was
7.8 ± 1.1% [12]. A subgroup analysis of patients
using continuous subcutaneous insulin
infusion treatment also failed to show a
significant HbA1c difference pre- and post-
CGM [12]. However, other studies support
improvements in glycemic control using
PCGM in different populations [6, 20, 21].
Boland and colleagues [22] used PCGM in
children with a mean HbA1c of 7.7% who were
considered to have effectively controlled fasting
glucoses. The PCGM showed over 90% of
patients had postprandial hyperglycemia, with
almost half getting levels over 300 mg/dL.
Almost 70% of the CGMs revealed frequent
and prolonged asymptomatic hypoglycemia
(glucose \60 mg/dL). The outcomes
unquestionably disclosed that PCGM is
relevant to improvement in diabetes
management [22]. It should be noted here that
real-time CGM was frequently removed by the
patients prior than planned, mainly due to lag
time between sensor and blood glucose, the
need for calibration, skin irritation, technical
problems, frequency of alarms, discomfort with
sensor, cost and concerns with false detection of
hypoglycemia, and failure to detect
hypoglycemia compared with standard home
monitoring [23]. However, the PCGM facilitate
with no alarms, better convenience and
minimum patient training compared with
real-time CGM, and it allows users see the
CGM data after it has been analyzed by a
healthcare professional.
Hypoglycemia is a potentially fatal event,
and people with T1DM describe severe
hypoglycemia as the most frightening and
feared event in their lives [24]. Studies have
shown greater detection of hypoglycemia, and
improved detection of severe hypoglycemia
with the use of PCGM helps patients to reduce
the number of episodes of hypoglycemia [25–
28]. In the present study, the authors found a
positive decline in the frequency of
hypoglycemia at 3 months in both male and
female patients. Similar results in the frequency
of hypoglycemia were observed in the different
age groups and the different treatment groups.
Fig. 2 The impact of professional continuous glucose monitoring on the frequency of hypoglycemia. Values are presented as
mean ± standard deviation. *Baseline vs. 3 months compared by t test
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It should be noted here, that when compared to
male patients, females showed a significant
reduction in the frequency of hypoglycemia
(P\0.05). The current findings are in
accordance with earlier studies which reported
that PCGM practice decreases self-reported
hypoglycemia [29].
The study has some limitations. Major
limitations of this study include: a relatively
small sample size; a limited number of risk
factors examined; limited social and
demographic factors; that it was performed at
a single center; and that there was no control
group with which to compare the study group.
Therefore, results may not be generalizable to
real-world situations. More studies on a larger
scale are needed to address the limitations
indicated in this study. Despite the
limitations, the study delivers valuable data
and creates awareness about the utility of
CGM among patients with T1DM in Saudi
Arabia.
CONCLUSION
While PCGM is a feasible preference for
glycemic control, the use of PCGM should also
be considered for patients with T1DM as it
reduces HbA1c levels and the frequency of
hypoglycemia. It is an initial step towards
reaching the ideal diabetes management
technology, one that is a closed-loop system.
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